CULVER CITY, Calif.--(BUSINESS WIRE)--NantOmics, LLC, the leader in molecular analyses and a member of the NantWorks ecosystem of companies, announced today the publication of peer-reviewed research defining for the first time three distinct classifications of sebaceous carcinoma, a rare and sometimes deadly former of skin cancer.
A study published on May 14 in the journal Nature Communications shows that a signature analysis reveals three clinically distinct classes of sebaceous carcinoma. The research offers fresh insights into how to treat the disease and adds more data to the concept that different mutational processes drive cancers that originate in the same location but are clinically distinct.
Using the technology that drives NantHealth, Inc.’s (NASDAQ: NH) GPS Cancer® platform, NantOmics scientists performed tumor-normal DNA sequencing and RNA sequencing on tissue samples from 32 patients with sebaceous carcinoma, revealing that the cell of origin and mutation patterns defined three clinically distinct classes. These explain both cancer ontogeny and clinical course.
“This is the first time that we have been able to define sebaceous carcinoma into distinct molecular classifications with defined mutational signature profiles,” said Dr. Shahrooz Rabizadeh, Chief Scientific Officer at NantOmics. “We believe that our findings and the classifications have significant implications on patient treatment.”
Dr. Patrick Soon-Shiong, CEO and founder of NantOmics, said the research reiterated the importance of no longer treating cancer by anatomy, but based on biology.
“This research has helped to decode signatures that are based on the disease’s molecular profile,” Soon-Shiong said. “Beyond treatment implications, this shows the absolute importance of looking at cancer treatment from a biological perspective.”
Nature Communications is a peer-reviewed, open-access journal that publishes research on all areas of natural sciences. Papers published by the journal are considered to represent important advances in their fields of research.
Other highlights from the paper:
- A UV-damage signature classification predominates in ten of the 32 samples.
- Nine of the samples are classified by microsatellite instability (MSI) profiles, which has been shown to be responsive to and is approved for pembrolizumab (Keytruda®) use.
- The third classification, pauci-mutational sebaceous carcinoma has a more varied signature, but half of which shared a similar mutation pattern in ZNF750 transcription factor in this study.
- Neoepitope analysis identified a subset of patients with highly clonal mutation burden that may be most responsive to immunotherapy, and may potentially be strong candidates for treatment with neoepitope vaccines.
About NantOmics, LLC
NantOmics, a member of the NantWorks ecosystem of companies, delivers molecular analysis capabilities with the intent of providing actionable intelligence and molecularly driven decision support for cancer patients and their providers at the point of care. NantOmics is the first molecular testing company to pioneer an integrated approach to unearthing the genomic and proteomic variances that initiate and drive cancer, by analyzing both normal and tumor cells from the same patient and following identified variances through from DNA to RNA to protein to drug. NantOmics has a highly scalable cloud-based infrastructure capable of storing and processing thousands of genomes a day, computing genomic variances in near real-time, and correlating proteomic pathway analysis with quantitative multi-plexed protein expression analysis from the same micro-dissected tumor sample used for genomic analysis. For more information please visit www.nantomics.com and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.
About NantHealth, Inc.
NantHealth, Inc., a member of the NantWorks ecosystem of companies, is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. NantHealth's unique systems-based approach to personalized healthcare applies novel diagnostics tailored to the specific molecular profiles of patient tissue and integrates this molecular data in a clinical setting with large-scale, real-time biometric signal and phenotypic data to track patient outcomes and deliver precision medicine. For nearly a decade, NantHealth has developed an adaptive learning system that integrates our unique molecular profiling solution, software and hardware. Our system infrastructure collects, indexes, analyzes and interprets billions of molecular, clinical, operational and financial data points derived from novel and traditional sources to continuously improve decision-making and optimize our clinical pathways and decision algorithms over time. For more information please visit http://www.nanthealth.com/.
About GPS Cancer®
GPS Cancer® is a unique, comprehensive test available through NantHealth. GPS Cancer integrates tumor/normal DNA and RNA sequencing, with enhanced expression analysis and bioinformatics of complex biologic pathway systems, providing oncologists with a comprehensive molecular profile of a patient’s cancer to inform personalized treatment strategies. GPS Cancer testing is conducted in CLIA-certified and CAP-accredited laboratories. For more information, visit www.gpscancer.com.